Latest Period
Q4 2025
Security Snapshot
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) Institutional Ownership
CUSIP: 00439U104
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
22
Shares (Excl. Options)
4,327,617
Price
$3.46
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- GRCE on Nasdaq
- Shares outstanding
- 16,654,455
- Price per share
- $3.33
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 4,327,617
- Total reported value
- $14,995,992
- % of total 13F portfolios
- 0%
- Share change
- +620,790
- Value change
- +$2,269,248
- Number of holders
- 22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 00439U104.
- 22 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 22 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $14,995,992 to $107,305.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 22 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 00439U104?
CUSIP 00439U104 identifies GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00439U104:
Significant Owners of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 9.9% | $5,836,720 | 1,648,791 | ADAR1 Capital Management GP, LLC | 31 Dec 2025 | |||
| Nantahala Capital Management, LLC | 10% | 0% | $5,616,773 | +$646,500 | 1,586,659 | +13% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| HIRSCHMAN ORIN | 5.9% | -40% | $3,157,115 | -$1,444,764 | 907,217 | -31% | Orin Hirschman | 31 Dec 2025 |
As of 31 Dec 2025, 22 institutional investors reported holding 4,327,617 shares of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE). This represents 26% of the company’s total 16,654,455 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 7.1% | 1,178,203 | 0% | 0.24% | $4,076,582 |
| AIGH Capital Management LLC | 5.4% | 907,217 | 0% | 0.93% | $3,146,077 |
| ADAR1 Capital Management, LLC | 3.9% | 641,988 | +83% | 0.17% | $2,221,278 |
| BANK OF AMERICA CORP /DE/ | 3% | 494,698 | 0% | 0% | $1,711,655 |
| VANGUARD GROUP INC | 2.5% | 423,981 | +3.6% | 0% | $1,479,694 |
| Cerity Partners LLC | 2.5% | 422,732 | 0% | $1,462,653 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.78% | 129,781 | +53% | 0% | $449,042 |
| CITADEL ADVISORS LLC | 0.25% | 42,297 | +55% | 0% | $147,617 |
| XTX Topco Ltd | 0.18% | 30,261 | 0% | $105,611 | |
| MORGAN STANLEY | 0.15% | 25,448 | +1277% | 0% | $88,050 |
| GSA CAPITAL PARTNERS LLP | 0.08% | 13,774 | 0% | $48,000 | |
| Stratos Wealth Partners, LTD. | 0.07% | 11,182 | 0% | $38,690 | |
| NATIONAL BANK OF CANADA /FI/ | 0.02% | 2,716 | 0% | 0% | $9,370 |
| Tower Research Capital LLC (TRC) | 0.01% | 1,945 | +21% | 0% | $6,730 |
| BNP PARIBAS FINANCIAL MARKETS | 0% | 600 | 0% | 0% | $2,076 |
| ROYAL BANK OF CANADA | 0% | 543 | 0% | 0% | $2,000 |
| Activest Wealth Management | 0% | 104 | 0% | 0% | $360 |
| SBI Securities Co., Ltd. | 0% | 101 | 0% | 0% | $349 |
| Steward Partners Investment Advisory, LLC | 0% | 41 | 0% | 0% | $142 |
| FLAGSHIP HARBOR ADVISORS, LLC | 0% | 2 | 0% | $7 | |
| NBC SECURITIES, INC. | 0% | 2 | 0% | 0% | $6 |
| Federation des caisses Desjardins du Quebec | 0% | 1 | 0% | 0% | $3 |
| SeaCrest Wealth Management, LLC | 0% | 0 | -100% | $0 | |
| CITIGROUP INC | 0% | 0 | -100% | $0 | |
| Stonepine Capital Management, LLC | 0% | 0 | -100% | $0 |
Institutional Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 23,176 | $107,305 | -$3,078,427 | $4.63 | 5 |
| 2025 Q4 | 4,327,617 | $14,995,992 | +$2,269,248 | $3.46 | 22 |
| 2025 Q3 | 3,706,227 | $11,033,102 | -$328,360 | $2.98 | 20 |
| 2025 Q2 | 3,816,908 | $11,344,205 | -$607,725 | $2.97 | 20 |
| 2025 Q1 | 4,024,092 | $9,168,718 | +$4,408,642 | $2.28 | 17 |
| 2024 Q4 | 2,087,877 | $7,835,456 | +$4,246,540 | $3.74 | 15 |
| 2024 Q3 | 959,571 | $2,878,713 | +$2,878,713 | $3.00 | 1 |